yahoo_financeOriginal article
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Data ReadoutpositiveLIVMARLIPositive
AI Analysis
Summary
Mirum Pharmaceuticals announced that its LIVMARLI study achieved key primary endpoints in patients with rare liver diseases. The positive data readout represents significant clinical progress for the company's rare disease program.
Clinical Trial Data
Primary Endpoint
Met
Importance:7/10
Sentiment:
0.70
rare diseaseliver diseaseclinical trialLIVMARLIendpoint achievement
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 3:02 PM